Evidence map›Paper›PMID 42040565›Full record

ArticleFrontiers in medicine2026

A case of recurrent RESLES type I: analysis of pathogenic factors and delayed imaging manifestations.

Zhihui Yu, Zhongxun He, Kang Du, Daijun Zhang, Hongzhi Wan, Mengting Shi, Haohao Wu, Yunli Yu

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhihui Yu *Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Zhongxun He *Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Kang Du *Department of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Daijun ZhangDepartment of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Hongzhi WanDepartment of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Mengting ShiDepartment of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Haohao WuDepartment of Neurology, Yunnan Qujing Central Hospital (Qujing First People's Hospital), Qujing, Yunnan, China.
Yunli YuDepartment of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reversible splenial lesion syndrome (RESLES) is a clinico-radiological syndrome characterized by a reversible lesion in the splenium of the corpus callosum. It is more common in children, and most patients recover completely with active treatment. However, recurrent RESLES is very rare and its etiology is unknown, posing significant challenges for clinicians in terms of prediction, diagnosis, and treatment. This article reports the first case of RESLES Type I in a young adult with five episodes and identifiable predisposing factors (intracranial infection and immunosuppressant dependence). By analyzing the patient's medical history, neuroimaging characteristics, body fluid test results, and response to immunomodulatory therapy, and reviewing recent literature on recurrent RESLES. The findings suggest that intracranial infection and immune dysfunction may be potential factors leading to the recurrence of RESLES Type I in this case, while serum sodium levels can remain within the normal range. Furthermore, we observed that infe cranial MRI lesions associated with RESLES in this patient often appeared 4-7 days after symptom onset, indicating a potential delay in imaging changes. Therefore, it is recommended that clinicians select appropriate timing for neuroimaging examinations and consider repeat scanning when necessary to reduce the risk of misdiagnosis or missed diagnosis.

Indexed as

high recurrenceimmunotherapyMRI delayed effectpredisposing factorsRESLES

Identifiers

PMID42040565
PMCPMC13105957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.